Novanta マネジメント
マネジメント 基準チェック /44
Novantaの CEO はMatthijs Glastraで、 Sep2016年に任命され、 の在任期間は 9.67年です。 の年間総報酬は$ 10.04Mで、 8.6%給与と91.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.27%を直接所有しており、その価値は$ 15.48M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と5年です。
主要情報
Matthijs Glastra
最高経営責任者
US$10.0m
報酬総額
| CEO給与比率 | 8.59% |
| CEO在任期間 | 9.7yrs |
| CEOの所有権 | 0.3% |
| 経営陣の平均在職期間 | 3.3yrs |
| 取締役会の平均在任期間 | 5yrs |
経営陣の近況
Recent updates
分析記事 • May 15
Novanta Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
It's been a pretty great week for Novanta Inc. ( NASDAQ:NOVT ) shareholders, with its shares surging 14% to US$156 in...
ナラティブの更新 • Apr 19
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.ナラティブの更新 • Apr 05
NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.ナラティブの更新 • Mar 22
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.ナラティブの更新 • Mar 06
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.ナラティブの更新 • Feb 20
NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple
Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.ナラティブの更新 • Feb 06
NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals
Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).ナラティブの更新 • Jan 22
NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals
Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.ナラティブの更新 • Jan 08
NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.ナラティブの更新 • Dec 24
NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.ナラティブの更新 • Dec 10
NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value
Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).ナラティブの更新 • Nov 26
NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward
Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.ナラティブの更新 • Nov 10
NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside
Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.分析記事 • Oct 28
Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump
Novanta Inc. ( NASDAQ:NOVT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...分析記事 • Oct 07
Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?
Novanta Inc. ( NASDAQ:NOVT ), is not the largest company out there, but it received a lot of attention from a...Seeking Alpha • Sep 29
Novanta: The Solution To Elevated Expectations Is Lower Prices
Summary Novanta Inc. remains a trusted technology partner for OEMs, but recent growth has been modest and organic performance underwhelming. Despite a strong track record and niche positioning, Novanta trades at a demanding 30x earnings multiple, currently posting quite flattish growth. Recent results show minimal sales and earnings growth, while NOVT leverage is set to rise due to a $200 million buyback program. I remain on the sidelines, seeking a lower entry point and a higher earnings yield to justify NOVT stock's premium and ensure a margin of safety. Read the full article on Seeking Alpha分析記事 • Sep 13
Novanta's (NASDAQ:NOVT) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...ナラティブの更新 • Sep 05
Robotics And Healthcare Demand Will Expand Market Opportunities
Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.分析記事 • Aug 29
Novanta Inc.'s (NASDAQ:NOVT) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 69.2x Novanta Inc. ( NASDAQ:NOVT ) may be sending very bearish signals at...分析記事 • Jun 16
Are Novanta Inc. (NASDAQ:NOVT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for Novanta is US$95.22 based on 2 Stage Free Cash Flow to Equity Novanta is...Seeking Alpha • Apr 06
Novanta: A Trusted Yet Premium Technology Partner
Summary Novanta has shown solid growth over the past decade, but growth has been a bit sluggish in recent years. The company is a key technology partner for global OEMs, with balanced revenue from advanced industrial and medical applications, boasting strong EBITDA margins. Despite a recent acquisition and increased sales, competitive dynamics, and macroeconomic challenges have pressured growth; shares are now trading at a lower, yet still premium, multiple. With debt reduced and growth returning, shares deserve a premium, but need to fall below $100 for a more attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Jan 01
Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Summary Novanta's Q3 results show revenue growth but a decline in gross margin and shipment deferrals, indicating prolonged challenges. Macroeconomic pressures, including weak demand and high interest rates, are hindering recovery in the life sciences sector. The company's book-to-bill ratio below 1 signals weakening demand, and its high debt levels add to the risk. Novanta’s valuation is too high given its low growth prospects, especially compared to more promising peers. As a result of these factors, Novanta is downgraded from a hold to a sell, as its current price does not justify the risks. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Summary Novanta Inc. is a leading tech provider facing macroeconomic headwinds and a soft demand climate, which have pressured its revenue and profitability. Despite strong fundamentals and a solid market position, its current high valuation makes it a risky investment. NOVT has managed modest revenue growth but struggles with significant inflationary challenges. For now, a Hold rating is recommended as the stock's valuation does not align with its performance amidst ongoing market uncertainties. Read the full article on Seeking Alpha
新しいナラティブ • Aug 28
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Apr 03 2026 | n/a | n/a | US$54m |
| Dec 31 2025 | US$10m | US$863k | US$54m |
| Sep 26 2025 | n/a | n/a | US$53m |
| Jun 27 2025 | n/a | n/a | US$61m |
| Mar 28 2025 | n/a | n/a | US$71m |
| Dec 31 2024 | US$9m | US$826k | US$64m |
| Sep 27 2024 | n/a | n/a | US$60m |
| Jun 28 2024 | n/a | n/a | US$62m |
| Mar 29 2024 | n/a | n/a | US$69m |
| Dec 31 2023 | US$8m | US$784k | US$73m |
| Sep 29 2023 | n/a | n/a | US$76m |
| Jun 30 2023 | n/a | n/a | US$77m |
| Mar 31 2023 | n/a | n/a | US$73m |
| Dec 31 2022 | US$7m | US$731k | US$74m |
| Sep 30 2022 | n/a | n/a | US$73m |
| Jul 01 2022 | n/a | n/a | US$64m |
| Apr 01 2022 | n/a | n/a | US$58m |
| Dec 31 2021 | US$12m | US$690k | US$50m |
| Oct 01 2021 | n/a | n/a | US$49m |
| Jul 02 2021 | n/a | n/a | US$44m |
| Apr 02 2021 | n/a | n/a | US$44m |
| Dec 31 2020 | US$5m | US$625k | US$45m |
| Oct 02 2020 | n/a | n/a | US$41m |
| Jul 03 2020 | n/a | n/a | US$42m |
| Apr 03 2020 | n/a | n/a | US$40m |
| Dec 31 2019 | US$4m | US$640k | US$41m |
報酬と市場: Matthijsの 総報酬 ($USD 10.04M ) は、 US市場 ($USD 8.38M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Matthijsの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Matthijs Glastra (56 yo)
9.7yrs
在職期間
US$10,042,292
報酬
Mr. Matthijs Glastra serves as Independent Director at IDEX Corporation from February 21, 2025. He has been the Chief Executive Officer and Director of Novanta Inc. since September 1, 2016 and serves as it...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.7yrs | US$10.04m | 0.27% $ 15.5m | |
| Chief Financial Officer | 15.2yrs | US$4.76m | 0.37% $ 21.2m | |
| General Counsel & Corporate Secretary | less than a year | US$237.83k | データなし | |
| Co-Chief Operating Officer of Automation Enabling Technologies | 4.1yrs | US$2.26m | 0.045% $ 2.6m | |
| Co-Chief Operating Officer of Medical Solutions | 1.3yrs | US$3.94m | 0.0059% $ 334.2k | |
| Chief Accounting Officer & Corporate Controller | 1.8yrs | データなし | 0.025% $ 1.4m | |
| Corporate Finance Leader & IR | no data | データなし | データなし | |
| Chief Information Officer & Chief Information Security Officer | 5.3yrs | データなし | データなし | |
| Senior Vice President of Corporate Development | 2.5yrs | データなし | データなし | |
| Chief Human Resources Officer | 1yr | データなし | データなし | |
| Group President of Medical Solutions | 8.1yrs | データなし | データなし |
3.3yrs
平均在職期間
52.5yo
平均年齢
経験豊富な経営陣: NOVTの経営陣は 経験豊富 であると考えられます ( 3.3年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.7yrs | US$10.04m | 0.27% $ 15.5m | |
| Chairman Emeritus | 5yrs | US$233.48k | データなし | |
| Independent Director | less than a year | US$45.38k | データなし | |
| Independent Director | 1.8yrs | US$267.48k | 0.0053% $ 302.4k | |
| Independent Director | 3.9yrs | US$278.30k | 0.0099% $ 564.0k | |
| Independent Lead Director | 8yrs | US$317.48k | 0.016% $ 931.7k | |
| Independent Director | 5yrs | US$302.48k | 0.011% $ 628.7k | |
| Independent Director | 13.9yrs | US$279.98k | 0.0037% $ 211.1k | |
| Independent Director | 2yrs | US$269.98k | 0.0060% $ 341.6k | |
| Independent Director | 6yrs | US$282.48k | 0.013% $ 724.6k |
5.0yrs
平均在職期間
59.5yo
平均年齢
経験豊富なボード: NOVTの 取締役会 は 経験豊富 であると考えられます ( 5年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/31 04:05 |
| 終値 | 2026/05/29 00:00 |
| 収益 | 2026/04/03 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Novanta Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |
| Andrew Buscaglia | Berenberg |